Yonglin Pu to Humans
This is a "connection" page, showing publications Yonglin Pu has written about Humans.
Connection Strength
0.390
-
Whole-body tumor segmentation from PET/CT images using a two-stage cascaded neural network with camouflaged object detection mechanisms. Med Phys. 2023 Oct; 50(10):6151-6162.
Score: 0.030
-
Developing a clinical and PET/CT volumetric prognostic index for risk assessment and management of NSCLC patients after initial therapy. Front Biosci (Landmark Ed). 2022 01 12; 27(1):16.
Score: 0.028
-
The Relative Importance of Clinical and Socio-demographic Variables in Prognostic Prediction in Non-Small Cell Lung Cancer: A Variable Importance Approach. Med Care. 2020 05; 58(5):461-467.
Score: 0.025
-
An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2018 09; 123:136-141.
Score: 0.022
-
Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging. Eur J Nucl Med Mol Imaging. 2018 11; 45(12):2079-2092.
Score: 0.022
-
Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2017 Aug; 44(8):1275-1284.
Score: 0.020
-
Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer. Nucl Med Commun. 2017 Feb; 38(2):185-192.
Score: 0.020
-
Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times. Nucl Med Commun. 2016 Jan; 37(1):50-6.
Score: 0.018
-
Quantification of metabolic tumor activity and burden in patients with non-small-cell lung cancer: Is manual adjustment of semiautomatic gradient-based measurements necessary? Nucl Med Commun. 2015 Aug; 36(8):782-9.
Score: 0.018
-
A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2015 Jul; 89(1):43-9.
Score: 0.017
-
Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images. Radiology. 2015 Jun; 275(3):862-9.
Score: 0.017
-
Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol. 2013 Jan; 20(1):32-40.
Score: 0.014
-
Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer. Acta Radiol. 2012 Jun 01; 53(5):561-8.
Score: 0.014
-
Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer. Int J Comput Assist Radiol Surg. 2013 Mar; 8(2):181-91.
Score: 0.014
-
Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer. Acad Radiol. 2012 Jan; 19(1):69-77.
Score: 0.014
-
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012 Jan; 39(1):27-38.
Score: 0.014
-
Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors. Acta Radiol. 2010 Sep; 51(7):782-8.
Score: 0.013
-
FDG-PET/CT findings of a metastatic pituitary tumor. Cancer Imaging. 2010 Mar 18; 10:114-6.
Score: 0.012
-
A positive correlation between alpha-glutamate and glutamine on brain 1H-MR spectroscopy and neonatal seizures in moderate and severe hypoxic-ischemic encephalopathy. AJNR Am J Neuroradiol. 2008 Feb; 29(2):216.
Score: 0.010
-
High prevalence of pineal cysts in healthy adults demonstrated by high-resolution, noncontrast brain MR imaging. AJNR Am J Neuroradiol. 2007 Oct; 28(9):1706-9.
Score: 0.010
-
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
Score: 0.008
-
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 06 17; 137(24):3454-3459.
Score: 0.007
-
Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer. 2018 12; 65(12):e27417.
Score: 0.005
-
Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6. J Neurol. 2016 Nov; 263(11):2302-2307.
Score: 0.005
-
Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretenoin alone or observation. Pediatr Blood Cancer. 2014 Jun; 61(6):1104-6.
Score: 0.004
-
Clinical utility of temporal subtraction images in successive whole-body bone scans: evaluation in a prospective clinical study. J Digit Imaging. 2011 Aug; 24(4):680-7.
Score: 0.003
-
Usefulness of temporal subtraction images for identification of interval changes in successive whole-body bone scans: JAFROC analysis of radiologists' performance. Acad Radiol. 2007 Aug; 14(8):959-66.
Score: 0.003
-
Development of a computer-aided diagnostic scheme for detection of interval changes in successive whole-body bone scans. Med Phys. 2007 Jan; 34(1):25-36.
Score: 0.002
-
Integrating PET and CT information to improve diagnostic accuracy for lung nodules: A semiautomatic computer-aided method. J Nucl Med. 2006 Jul; 47(7):1075-80.
Score: 0.002